63 related articles for article (PubMed ID: 8779223)
1. Metabolism of pimobendan in long-term human hepatocyte culture: in vivo-in vitro comparison.
Pahernik SA; Schmid J; Sauter T; Schildberg FW; Koebe HG
Xenobiotica; 1995 Aug; 25(8):811-23. PubMed ID: 8779223
[TBL] [Abstract][Full Text] [Related]
2. Identification of cytochrome P-450 isoform(s) responsible for the metabolism of pimobendan in human liver microsomes.
Kuriya Si; Ohmori S; Hino M; Ishii I; Nakamura H; Senda C; Igarashi T; Kiuchi M; Kitada M
Drug Metab Dispos; 2000 Jan; 28(1):73-8. PubMed ID: 10611143
[TBL] [Abstract][Full Text] [Related]
3. Collagen gel immobilization: a useful cell culture technique for long-term metabolic studies on human hepatocytes.
Koebe HG; Pahernik S; Eyer P; Schildberg FW
Xenobiotica; 1994 Feb; 24(2):95-107. PubMed ID: 8017092
[TBL] [Abstract][Full Text] [Related]
4. Electrophysiological actions of the pimobendan metabolite, UD-CG 212 Cl, in guinea pig myocardium.
Westfall MV; Wahler GM; Fujino K; Solaro RJ
J Pharmacol Exp Ther; 1992 Jan; 260(1):58-63. PubMed ID: 1346167
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of enantiomers of pimobendan in patients with dilated cardiomyopathy and congestive heart failure after single and repeated oral dosing.
Chu KM; Shieh SM; Hu OY
Clin Pharmacol Ther; 1995 Jun; 57(6):610-21. PubMed ID: 7781260
[TBL] [Abstract][Full Text] [Related]
6. Pimobendan. A review of its pharmacology and therapeutic potential in congestive heart failure.
Fitton A; Brogden RN
Drugs Aging; 1994 May; 4(5):417-41. PubMed ID: 8043944
[TBL] [Abstract][Full Text] [Related]
7. Use of organotypical cultures of primary hepatocytes to analyse drug biotransformation in man and animals.
Bader A; Zech K; Crome O; Christians U; Ringe B; Pichlmayr R; Sewing KF
Xenobiotica; 1994 Jul; 24(7):623-33. PubMed ID: 7975727
[TBL] [Abstract][Full Text] [Related]
8. Investigation of the in vitro metabolism profile of a phosphodiesterase-IV inhibitor, CDP-840: leading to structural optimization.
Li C; Chauret N; Trimble LA; Nicoll-Griffith DA; Silva JM; MacDonald D; Perrier H; Yergey JA; Parton T; Alexander RP; Warrellow GJ
Drug Metab Dispos; 2001 Mar; 29(3):232-41. PubMed ID: 11181489
[TBL] [Abstract][Full Text] [Related]
9. Effects of the benzimidazole derivatives pimobendan and 2-(4-hydroxy-phenyl)-5-(5-methyl-3-oxo-4,5-dihydro-2H-6- pyridazinyl) benzimidazole . HCl on phosphodiesterase activity and force of contraction in guinea-pig hearts.
Berger C; Meyer W; Scholz H; Starbatty J
Arzneimittelforschung; 1985; 35(11):1668-73. PubMed ID: 2418846
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy of pimobendan (UD-CG 115 BS) in patients with chronic congestive heart failure.
Baumann G; Ningel K; Permanetter B
J Cardiovasc Pharmacol; 1989; 14 Suppl 2():S23-30. PubMed ID: 2478788
[TBL] [Abstract][Full Text] [Related]
11. Correlations between the cardiovascular effects of pimobendan and plasma concentrations of the parent compound and of its major active metabolite, UD-CG 212 CL, in patients with congestive heart failure.
Hagemeijer F; Roth W; Brand HJ
J Cardiovasc Pharmacol; 1989; 14 Suppl 2():S57-64. PubMed ID: 2478794
[TBL] [Abstract][Full Text] [Related]
12. In vitro metabolism of the new cardiotonic agent denopamine (TA-064) by rat and rabbit liver preparations. Oxidation, methylation, and glucuronidation.
Suzuki T; Hashimura Y; Takeyama S
Drug Metab Dispos; 1985; 13(2):246-54. PubMed ID: 2859176
[TBL] [Abstract][Full Text] [Related]
13. Acute and long-term hemodynamic effects of pimobendan (UD-CG 115 BS) in comparison with captopril.
Hauf GF; Grom E; Jähnchen E; Roskamm H
J Cardiovasc Pharmacol; 1989; 14 Suppl 2():S49-56. PubMed ID: 2478793
[TBL] [Abstract][Full Text] [Related]
14. Effects of pimobendan and its metabolite on myofibrillar calcium responsiveness and ATPase activity in the presence of inorganic phosphate.
van Meel JC; Entzeroth M; Redemann N; Haigh RM
Arzneimittelforschung; 1995 Feb; 45(2):136-41. PubMed ID: 7710434
[TBL] [Abstract][Full Text] [Related]
15. Single-dose pharmacokinetics and cardiovascular effects of oral pimobendan in healthy cats.
Yata M; McLachlan AJ; Foster DJ; Hanzlicek AS; Beijerink NJ
J Vet Cardiol; 2016 Dec; 18(4):310-325. PubMed ID: 27613648
[TBL] [Abstract][Full Text] [Related]
16. Cardiac electrophysiologic and hemodynamic activity of pimobendan (UD-CG 115 BS), a new inotropic agent.
Kitzen JM; Lynch JJ; Driscoll EM; Lucchesi BR
J Pharmacol Exp Ther; 1988 Mar; 244(3):929-39. PubMed ID: 3252039
[TBL] [Abstract][Full Text] [Related]
17. Phase II metabolism of warfarin in primary culture of adult rat hepatocytes.
Jansing RL; Chao ES; Kaminsky LS
Mol Pharmacol; 1992 Jan; 41(1):209-15. PubMed ID: 1732719
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular effect and simultaneous pharmacokinetic and pharmacodynamic modeling of pimobendan in healthy normal subjects.
Chu KM; Hu OY; Shieh SM
Drug Metab Dispos; 1999 Jun; 27(6):701-9. PubMed ID: 10348800
[TBL] [Abstract][Full Text] [Related]
19. Metabolism of prazosin in rat, dog, and human liver microsomes and cryopreserved rat and human hepatocytes and characterization of metabolites by liquid chromatography/tandem mass spectrometry.
Erve JC; Vashishtha SC; DeMaio W; Talaat RE
Drug Metab Dispos; 2007 Jun; 35(6):908-16. PubMed ID: 17353349
[TBL] [Abstract][Full Text] [Related]
20. Calcium sensitization with pimobendan: pharmacology, haemodynamic improvement, and sudden death in patients with chronic congestive heart failure.
Hagemeijer F
Eur Heart J; 1993 Apr; 14(4):551-66. PubMed ID: 8472722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
